Regulus slips after latest round of HCV data

Regulus Therapeutics Inc. (NASDAQ:RGLS) presented updated interim HCV data on Friday from a 79-patient Phase II trial of a four-week regimen of RG-101 plus a direct-acting antiviral (DAA). The company shed $0.90

Read the full 324 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE